GLP Agonist
Semaglutide
Semaglutide is a long-acting, acylated GLP-1 analogue with approximately 94% homology to native GLP-1. Its extended half-life (~7 days) enables once-weekly dosing paradigms in research protocols. Preclinical and clinical evidence supports robust body weight reduction (≥15% in sustained trials), cardiovascular risk reduction, and neuroprotective effects in Parkinson's disease models, expanding its research relevance beyond metabolic disease.
Mechanism of Action
Selective GLP-1 receptor agonism stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and activates hypothalamic satiety centers via receptor-mediated signaling.
Research Applications
- → Chronic weight management studies
- → Cardiovascular outcomes research (MACE reduction)
- → Neurodegeneration models (Parkinson's, Alzheimer's)
- → NAFLD/NASH therapeutic investigation
Analytical Validation
HPLC purity ≥ 98.5%; endotoxin < 1 EU/mg; molecular weight 4113.6 Da confirmed by LC-MS; water content ≤ 6% (Karl Fischer).
For research use only